Realbotix Corp. (OTCQB: XBOTF) – The Robotics Company With No Competition | Marathon Money Inside the Ticker
Realbotix aims to redefine humanoid robotics with advanced technology.
Azure Holding Group (AZRH) Skyrockets from Pennies to Powerhouse – $0.03 to $0.24 and Climbing!
Azure Holding Group rapidly grows as an emerging oilfield contender.
Memory Protocol: Could This Be the Future of Owning Our Digital Selves? $MEM
Memory Protocol token ($MEM)
Marathon Money: Why Azure Holding Group (AZRH) Could Be the Next $25 Stock in 2–3 Years
The Setup Nobody Is Talking About Every once in a while, the market presents a stock that looks invisible to most investors—trading quietly on the OTC, thinly traded, ignored by…
$AZRH Stock | Marathon Money Interviews Vision Oil & Gas CEO Joshua Cohen
Vision Oil & Gas evolves into a significant U.S. oil operator.
Inside CURR: Kevin Chen Breaks Down the Future of CURRENC Group Inc.
I recently had the opportunity to sit down with Kevin Chen, a member of the Board of Directors at CURRENC Group Inc. (NASDAQ: CURR) since August 2024. Kevin, who also…
Mobilicom (NASDAQ: MOB) CEO Oren Elkayam: Inside the Future of Drone Cybersecurity
Join host Kenny Colin from the Marathon Money Podcast for an exclusive 40-minute sit-down with the CEO of Mobilicom (NASDAQ: MOB)! In this deep dive, we explore how Mobilicom is…
CEO Wes Cummins Sits With Marathon Money: Applied Digital & The Future of AI Data Center Performance Computing Interview
AI is transforming everything, and legacy data centers simply can’t handle the demand. That’s where Applied Digital (APLD) steps in—a next-generation AI infrastructure company building purpose-built, high-density, liquid-cooled data centers…
Marathon Money Exclusive: Coya Therapeutics CEO Arun Swaminathan on Revolutionizing Neurodegenerative Treatments and a $700M Partnership
In our latest episode of Marathon Money, we had the privilege of sitting down with Dr. Arun Swaminathan, CEO of Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company shaking up…
Marathon Money Exclusive: OS Therapies (NYSE: OSTX) CBO Interview Reveals FDA Meeting In Q2 2025 Milestones, $150M Revenue Boost, and $500M Market Opportunity
In this in-depth conversation, we dive straight into the company’s bold plans for the next 12 to 18 months: Spoiler Alert: Minute 29 is a must-watch. This is where we…